J&J says ustekinumab outperformed Amgen drug for psoriasis

09/19/2008 | Wall Street Journal, The · Forbes

Johnson & Johnson unveiled results from a 903-patient study showing that its experimental drug ustekinumab beat Enbrel -- a medicine co-marketed by Amgen and Wyeth -- in treating moderate to severe psoriasis. An Amgen spokeswoman said Enbrel has a "consistent safety profile" and that data from the J&J-funded trial do not prove ustekinumab's long-term safety.

View Full Article in:

Wall Street Journal, The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT